Dianthus Therapeutics

Dianthus Therapeutics

Yahoo Finance • 20 days ago

Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?

Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullba... Full story

Yahoo Finance • last month

UiPath downgraded, Shell upgraded: Wall Street's top analyst calls

UiPath downgraded, Shell upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by... Full story

Yahoo Finance • 2 months ago

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

Investors choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) must weigh the high-growth potential of specialized U.S. biotech against a more stable, dividend-paying global healt... Full story

Yahoo Finance • 2 months ago

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe auto... Full story

Yahoo Finance • 4 months ago

Stocks Settle Sharply Lower on Escalating Middle East Tensions

The S&P 500 Index ($SPX) (SPY) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.87%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -1.98%.  June E-mini S&P futures (ESM26) fell -1.62%, and... Full story

Yahoo Finance • 4 months ago

Stocks Resume Decline as Chipmakers and AI Companies Fall

The S&P 500 Index ($SPX) (SPY) today is down -0.61%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.88%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.80%.  June E-mini S&P futures (ESM26) are down -0.71%, and June E-mini Na... Full story

Yahoo Finance • 4 months ago

Stocks Fall on Weakness in Tech and Trucking Companies

The S&P 500 Index ($SPX) (SPY) today is down -0.28%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.38%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.28%.  June E-mini S&P futures (ESM26) are down -0.25%, and June E-mini Na... Full story

Yahoo Finance • 4 months ago

Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK

The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story

Yahoo Finance • 4 months ago

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125.... Full story

Yahoo Finance • 5 months ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SE... Full story

Yahoo Finance • 5 months ago

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

On May 15, 2026, Cormorant Asset Management disclosed a new position in Dianthus Therapeutics(NASDAQ:DNTH), acquiring 950,000 shares in an estimated $55.01 million trade based on quarterly average pricing. What happened According to a Se... Full story

Yahoo Finance • 5 months ago

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • 5 months ago

LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis

NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's dise... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

Key Points 8,224 shares (~$739,000) of common stock were sold on April 9, 2026, at a weighted average price of around $89.84 per share. This transaction represented 100.00% of Mr. Savitz's direct common stock holdings, reducing his direct... Full story

Yahoo Finance • 6 months ago

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe aut... Full story

Yahoo Finance • 7 months ago

Dianthus rises as FDA agrees with proposed changes to lead program

[FDA Headquarters] Shares of Dianthus Therapeutics (DNTH [https://seekingalpha.com/symbol/DNTH]) spiked on Thursday after the company announced that the FDA agreed with several proposed changes related to clinical development of its lead... Full story

Yahoo Finance • 7 months ago

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 7 months ago

Dianthus Prices $625 Mln Offering To Advance Claseprubart And Broader Autoimmune Pipeline; Stock Up

(RTTNews) - Dianthus Therapeutics, Inc. (DNTH) has priced an upsized $625 million underwritten public offering as the clinical-stage biotech prepares to advance multiple programs targeting severe autoimmune and neuromuscular diseases. The... Full story

Yahoo Finance • 7 months ago

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transfo... Full story

Yahoo Finance • 7 months ago

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)

Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The fi... Full story